REDUCING MORTALITY IN ADULTS WITH ADVANCED HIV DISEASE (REVIVE)
Phase 3
- Conditions
- HIV/AIDS
- Registration Number
- PACTR202302799565020
- Lead Sponsor
- Population Health Research Institute
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 8000
Inclusion Criteria
Age = 18 years
Documented HIV infection
CD4 count criteria:
CD4 count = 100 cells/mm3 within past 30 days if on ART; or
Documented CD4 nadir = 100 cells/mm3 and complete interruption of ART for = 6 months; or
Documented CD4 count = 100 cells/mm3 if ART-naive
Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 2 weeks of enrolment
Exclusion Criteria
Contraindications to azithromycin:
Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or
Personal or family history of QT-prolongation
Severe illness requiring immediate or continued hospitalisation*
*This will be in the judgement of site investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method